Illumina, Inc.

Equities

ILMN

US4523271090

Market Closed - Nasdaq Other stock markets 08:00:00 13/02/26 am AEDT			5-day change	1st Jan Change
114.44 ^USD	-1.67%		-14.35%	-12.75%

07/02	UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating	MT
06/02	Illumina, Inc., Q4 2025 Earnings Call, Feb 05, 2026

Transcript : Illumina, Inc., Q2 2025 Earnings Call, Jul 31, 2025

Published on 08/01/2025 at 07:46 am AEST - Modified on 08/01/2025 at 02:35 pm AEST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, ladies and gentlemen. Welcome to the Second Quarter 2025 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Illumina, Inc.

07/02	UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating	MT
06/02	Illumina, Inc., Q4 2025 Earnings Call, Feb 05, 2026
06/02	Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2026	CI
06/02	Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set	MT
06/02	Earnings Flash (ILMN) Illumina, Inc. Posts Q4 Adjusted EPS $1.35 per Share, vs. FactSet Est of $1.24	MT
06/02	Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B	MT
06/02	Illumina, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
04/02	Illumina, Inc. and the San Diego Zoo Wildlife Alliance Partner to Sequence the Frozen Zoo	CI
31/01	Illumina, Inc. completed the acquisition of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd from Standard BioTools Inc..	CI
31/01	Standard BioTools Completes $350 Million Sale of SomaLogic to Illuminia	MT
29/01	The Dollar's Drop Is a Warning Shot
28/01	Devyser Enters Strategic Agreement with Illumina	FW
28/01	Devyser Enters Strategic Supply Agreement with Illumina to Offer Sequencing Instruments and Products	CI
27/01	Spenda Limited Announces Resignation of Francis Desouza as an Executive and Director, Effective January 27, 2026	CI
21/01	Illumina Secures Reimbursement of Nearly $3,000 Per TruSight Test	MT
21/01	Illumina, Inc. Secures CMS Reimbursement for TruSight Oncology Comprehensive, Expanding Access to Precision Oncology	CI
21/01	Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology	RE
16/01	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
14/01	Illumina CEO Sees Big Growth Opportunity in China	MT
14/01	Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company	CI
14/01	Illumina, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 07:30 AM
14/01	Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset	RE
14/01	Illumina introduces billion cell atlas to accelerate AI and drug discovery	RE
14/01	Illumina unveils dataset to speed up AI-powered drug discovery	RE
14/01	Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery	MT